Clinical trials
Observational Bacterial Infections trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 7 |
| Completed | 5 |
| Enrolling by invitation | 2 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Qilu Hospital of Shandong University | 2 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2 |
| Beijing YouAn Hospital | 1 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 1 |
| Duke University | 1 |
| Ruijin Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Shandong University | 1 |
| Sir Run Run Shaw Hospital | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bacterial Infections | 16 |
| Virus Diseases | 4 |
| Sepsis | 3 |
| Fibrosis | 2 |
| Liver Cirrhosis | 2 |
| Mycoses | 2 |
| Pneumonia | 2 |
| Acute Kidney Injury | 1 |
| Acute-On-Chronic Liver Failure | 1 |
| Ascites | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.